Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst
August 10, 2021 1:34 PM EDTEarlier today, Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced positive interim results from its ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers.
Results from the MAD portion of the trial demonstrated proof of biology as evidenced by a dose proportional induction in HBG mRNA and accompanying increases in HbF-containing reticulocytes... More
Fulcrum Therapeutics Inc. (FULC) Halted on LUDP, Up 114%
August 10, 2021 11:27 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) Halted on LUDP, Up 114%
